Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146054 | 0.85 | GPR139 (0.43) | GPR139 | |
| SCHEMBL31146145 | 0.82 | GPR139 (0.40) | GPR139 | |
| SCHEMBL31146060 | 0.82 | GPR139 (0.40) | GPR139 | |
| SCHEMBL31146077 | 0.81 | GPR139 (0.41) | GPR139 | |
| SCHEMBL31146112 | 0.81 | GPR139 (0.40) | GPR139 | |
| SCHEMBL31145973 | 0.80 | GPR139 (0.39) | GPR139 | |
| SCHEMBL31145971 | 0.78 | GPR139 (0.38) | GPR139 | |
| SCHEMBL31145923 | 0.78 | GPR139 (0.36) | KDM4EHSD17B10KMT2AMEN1GPR139 | |
| SCHEMBL31146050 | 0.78 | GPR139 (0.42) | KDM4EHSD17B10GPR139ALDH1A1 | |
| SCHEMBL31359130 | 0.76 | GPR139 (0.51) | KDM4EHSD17B10KMT2AMEN1GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| WO-2024206339-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | KDM4E 3988/4885HSD17B10 505/4885KMT2A 2432/4885 |
| US-20250026740-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, COQ8A | KDM4E 3988/4885HSD17B10 505/4885KMT2A 2432/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | KDM4E 4379/4885HSD17B10 940/4885KMT2A 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.